H3F3A — H3.3 Histone A

H3F3A — H3.3 Histone A

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">H3.3 Histone A</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>H3F3A</td></tr>
<tr><td><strong>Full Name</strong></td><td>H3.3 Histone A</td></tr>
<tr><td><strong>Chromosome</strong></td><td>1q42.12</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[3020](https://www.ncbi.nlm.nih.gov/gene/3020)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000163041</td></tr>
<tr><td><strong>OMIM ID</strong></td><td>601128</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P84243](https://www.uniprot.org/uniprot/P84243)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Histone variant (H3.3)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Diffuse Intrinsic Pontine Glioma, Neurodevelopmental Disorders, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease</td></tr>
</table>
</div>

H3F3A — H3.3 Histone A

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">H3.3 Histone A</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>H3F3A</td></tr>
<tr><td><strong>Full Name</strong></td><td>H3.3 Histone A</td></tr>
<tr><td><strong>Chromosome</strong></td><td>1q42.12</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[3020](https://www.ncbi.nlm.nih.gov/gene/3020)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000163041</td></tr>
<tr><td><strong>OMIM ID</strong></td><td>601128</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P84243](https://www.uniprot.org/uniprot/P84243)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Histone variant (H3.3)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Diffuse Intrinsic Pontine Glioma, Neurodevelopmental Disorders, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease</td></tr>
</table>
</div>

H3F3A encodes histone H3.3, a replication-independent histone variant that plays fundamental roles in chromatin regulation across eukaryotic cells. This protein has emerged as a critical factor in understanding both brain tumor development and neurodegenerative processes, with research linking H3.3 dynamics to conditions ranging from diffuse intrinsic pontine glioma to Alzheimer's, Parkinson's, and Huntington's diseases. The variant-specific amino acid residues distinguish H3.3 from canonical histones, enabling specialized functions in neuronal development, synaptic plasticity, and epigenetic maintenance that are essential for proper brain function throughout the lifespan [@h3f3a-neurons].

Overview

H3F3A encodes histone H3.3, a replication-independent histone variant that is a crucial component of chromatin regulation in eukaryotic cells. Unlike canonical histone H3.1, which is deposited during DNA replication, H3.3 is incorporated into chromatin throughout the cell cycle, particularly at transcriptionally active regions, telomeres, and pericentromeric heterochromatin [1](https://pubmed.ncbi.nlm.nih.gov/23217742/). This deposition is mediated by specific histone chaperone complexes, including DAXX/ATRX and HIRA, which ensure proper placement of H3.3 in distinct genomic regions.

In the central nervous system, H3.3 plays essential roles in neuronal development, activity-dependent gene expression, synaptic plasticity, and epigenetic regulation. The-brain-specific functions of H3.3 make it particularly relevant to understanding neurodegenerative diseases [@epigenetic-neurodegeneration]. Mutations in H3F3A, particularly the K27M substitution, are driver events in diffuse intrinsic pontine glioma (DIPG) [@h3k27m-glioma], while germline variants are associated with neurodevelopmental disorders. In [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [Huntington's disease](/diseases/huntingtons-disease), altered H3.3 dynamics and post-translational modifications affect chromatin accessibility and gene expression patterns critical for neuronal survival [3](https://pubmed.ncbi.nlm.nih.gov/25662928/).

Molecular Biology

Gene Structure and Evolution

The H3F3A gene is located on chromosome 1q42.12 and encodes the H3.3 histone variant. The gene structure is relatively simple, containing a single intron that separates the coding sequence from the 3'UTR, which is characteristic of histone genes that often lack introns in their coding regions. The genomic organization features a single exon encoding the histone fold domain, a 3' UTR with a stem-loop structure for processing, and the gene is conserved across vertebrates with a paralog, H3F3B, located on chromosome 17.

The H3.3 variant differs from canonical H3.1 at only 5 amino acid positions, yet these differences have profound functional consequences. The variant-specific residues determine interaction with specific chaperone complexes, genomic targeting patterns, and post-translational modification potential, allowing H3.3 to participate in distinct cellular processes that canonical H3.1 cannot perform.

Protein Structure

H3.3 is a 136-amino acid protein that forms the core of the nucleosome. The protein can be divided into distinct structural domains with specialized functions: the N-terminal tail (positions 1-40) contains multiple lysine residues that serve as sites for post-translational modifications including acetylation, methylation, and phosphorylation; the histone fold domain (positions 41-120) mediates dimerization and DNA binding within the nucleosome structure; and the C-terminal region (positions 121-136) contributes to structural stability of the nucleosome core particle.

| Domain | Position | Function |
|--------|----------|----------|
| N-terminal tail | 1-40 | Post-translational modifications |
| Histone fold | 41-120 | Dimerization, DNA binding |
| C-terminal | 121-136 | Structural stability |

These variant-specific residues at key positions differentiate H3.3 from H3.1. Position 31 contains serine in H3.3 versus alanine in H3.1, creating a potential phosphorylation site. Position 87 features serine in H3.3 versus glycine in H3.1, providing a modification site. Position 89 has alanine in H3.3 versus serine in H3.1, forming a regulatory region. These differences allow H3.3 to be recognized by specific chaperones and to carry distinct post-translational modifications that regulate its function.

Histone Deposition Pathways

H3.3 is deposited by two main pathways that target different genomic regions and serve distinct cellular functions. The HIRA-dependent pathway deposits H3.3 primarily in euchromatin at actively transcribed genes, occurring independently of DNA replication and associated with transcriptional activity. This pathway is particularly important during gene activation and supports the incorporation of H3.3 at regulatory regions that undergo dynamic chromatin remodeling during transcriptional responses.

The DAXX/ATRX-dependent pathway targets subtelomeric regions and is associated with heterochromatin formation, playing an important role in telomere maintenance and silencing of repetitive genomic elements. This pathway is mediated by interaction between H3.3 and the ATRX protein, and disruption of this pathway leads to aberrant chromatin states and disease phenotypes including telomere dysfunction and altered gene expression at chromosome ends.

Function in the Central Nervous System

Neuronal Development

H3.3 is essential for proper brain development, serving multiple critical functions in neural progenitor cells and differentiating neurons [@h3f3a-neurons]. The histone variant maintains neural progenitor cell proliferation while simultaneously facilitating neuronal differentiation by regulating gene expression programs that control the transition from proliferation to differentiation. During development, H3.3 establishes neuronal identity through epigenetic programming, maintains cell-type-specific chromatin states, and allows for activity-dependent reprogramming that adapts developing neurons to environmental signals and activity patterns.

Activity-Dependent Gene Expression

In mature neurons, H3.3 plays a critical role in neuronal activity by enabling rapid responses to stimulation. Upon neuronal activation, H3.3 is rapidly incorporated at immediate-early genes, facilitating transcriptional activation and supporting synaptic plasticity mechanisms that underlie learning and memory. Experience-dependent changes involve learning-induced H3.3 deposition at plasticity-related genes, where the histone variant contributes to memory consolidation mechanisms and regulates plasticity-related gene expression patterns that encode experience into neural circuits.

Synaptic Plasticity

H3.3 contributes to synaptic plasticity through multiple interconnected mechanisms involving chromatin remodeling at synaptic gene loci. The histone variant regulates synaptic gene expression, maintains activity-dependent changes in neuronal circuits, supports long-term potentiation processes, and enables dendritic spine remodeling that structuraly alters synaptic connections. Mice with H3.3 deficiency in neurons show impaired long-term potentiation, behavioral deficits in learning paradigms, and altered synaptic protein expression, demonstrating the essential role of H3.3 in maintaining proper synaptic function.

Chromatin Remodeling in Aging

In aging brains, H3.3 dynamics undergo significant changes that may contribute to age-related cognitive decline [@chromatin-neurobiology]. Altered deposition patterns affect where H3.3 is incorporated in the genome, while modified post-translational states change how the histone variant functions in chromatin regulation. These age-related changes impact neuronal gene expression patterns, particularly affecting genes involved in synaptic function, neuronal survival, and stress responses. Research suggests that H3.3 dynamics may serve as a molecular link between aging processes and neurodegenerative changes, though the precise mechanisms remain under investigation.

Disease Associations

Diffuse Intrinsic Pontine Glioma (DIPG)

The H3.3K27M mutation is the hallmark of DIPG, occurring in approximately 70-80% of DIPG cases and other diffuse midline gliomas, and is found in roughly 50% of pediatric high-grade gliomas [5](https://pubmed.ncbi.nlm.nih.gov/23431157/). This mutation involves a lysine to methionine substitution at position 27, which acts through a dominant-negative effect on polycomb repressive complex 2 (PRC2) to cause global reduction of H3K27me3 and aberrant gene expression patterns that drive tumorigenesis. The resulting epigenetic dysregulation activates oncogenic pathways while silencing genes that would normally suppress tumor growth. Therapeutic approaches under investigation include PRC2 inhibitors designed to restore normal H3K27me3 levels, epigenetic therapy approaches targeting the altered chromatin state, and strategies to target altered metabolic pathways that support tumor cell survival.

Neurodevelopmental Disorders

Germline H3F3A variants cause neurodevelopmental syndromes with distinct phenotypes depending on the specific mutation. H3.3 G34 mutants are associated with overgrowth syndromes characterized by developmental delay, craniofacial abnormalities, and rare neurological complications. These mutations alter deposition patterns and modify chromatin states during development, leading to aberrant gene regulation that disrupts normal brain development and body growth regulation. The mechanisms involve altered interaction with histone chaperones and modified post-translational modification patterns that affect the epigenetic landscape during critical developmental windows.

Alzheimer's Disease

Connections between H3F3A and Alzheimer's disease are evident through multiple lines of evidence examining epigenetic changes in affected brains [@epigenetic-neurodegeneration]. Chromatin changes include altered H3.3 incorporation patterns and modified H3K27me3 marks in Alzheimer's disease brains, creating aberrant epigenetic landscapes that may contribute to disease progression. Gene expression dysregulation affects neuronal genes, synaptic plasticity genes, and stress response pathways, disrupting the normal patterns of gene expression required for neuronal survival and function. The therapeutic potential lies in epigenetic therapies targeting histone modifications, approaches to modulating H3.3 dynamics, and PRC2 inhibitors currently in development for neurodegenerative conditions.

Parkinson's Disease

Connections to Parkinson's disease involve epigenetic alterations affecting dopaminergic neuron function and neuronal vulnerability [@epigenetic-neurodegeneration]. Changed H3.3 at dopaminergic neuron genes alters chromatin accessibility and transcriptional programs that are essential for the survival and function of these vulnerable neurons. Effects on survival genes, mitochondrial function genes, and protein homeostasis pathways may contribute to the selective vulnerability of dopaminergic neurons in Parkinson's disease, though the precise mechanistic connections continue to be elucidated.

Huntington's Disease

Connections to Huntington's disease center on transcriptional dysregulation caused by altered H3.3 dynamics and aberrant chromatin states [@epigenetic-neurodegeneration]. The histone variant plays a role in affected neuronal survival genes that become misregulated in Huntington's disease, contributing to the progressive loss of striatal neurons. Therapeutic implications include epigenetic approaches designed to restore proper gene expression patterns and strategies targeting altered histone modification patterns that may help maintain normal chromatin states in vulnerable neurons.

Expression Patterns

Brain Region Expression

| Region | Expression Level | Function |
|--------|------------------|----------|
| Cerebral cortex | High | Synaptic plasticity, cognition |
| Hippocampus | High | Memory formation |
| Cerebellum | Moderate | Motor learning |
| Basal ganglia | Moderate | Movement control |
| Brainstem | Moderate | Autonomic functions |
| Spinal cord | Low-moderate | Motor neuron function |

Cellular Expression

H3F3A expression varies across neural cell types, with the highest levels found in neurons, particularly excitatory neurons where the histone variant supports activity-dependent chromatin remodeling. Neural progenitors express high levels during development when rapid epigenetic changes guide cell fate decisions. Astrocytes show moderate expression, while oligodendrocytes and microglia display lower expression levels. This cell-type-specific pattern suggests that H3.3 functions are particularly important in cells with high transcriptional plasticity and activity-dependent gene regulation.

Developmental Regulation

H3F3A expression is highest during embryonic development, when rapid cell division and differentiation require extensive chromatin remodeling [@h3f3a-expression]. Expression remains high postnatally and is maintained into adulthood, reflecting the continued need for H3.3 in mature neurons. Age-related changes in distribution have been reported, with alterations in H3.3 localization and post-translational modification patterns observed in aging brains that may contribute to cognitive decline.

Therapeutic Approaches

Cancer Therapy

Targeting H3K27M in DIPG involves multiple therapeutic strategies under active investigation. Small molecule inhibitors of PRC2 aim to normalize the aberrant epigenetic state caused by the K27M mutation, while HDAC inhibitors and metabolic pathway modulators address related vulnerabilities in tumor cells. Combination approaches that target multiple pathways simultaneously may prove more effective than single-agent strategies, though delivery across the blood-brain barrier remains a significant challenge for all therapeutic modalities. Targeted delivery to tumors and overcoming resistance mechanisms are areas of active research.

Neurodegeneration Therapy

Epigenetic approaches to treating neurodegenerative diseases involving H3.3 include histone deacetylase inhibitors, PRC2 modulators, BET inhibitors, and strategies targeting metabolic-epigenetic crosstalk [@chromatin-neurobiology]. Key challenges include achieving proper distribution in the brain, balancing beneficial and harmful effects of chromatin-modifying agents, ensuring cell-type specificity to target vulnerable neurons while sparing others, and determining the optimal timing of intervention relative to disease stage. The complexity of H3.3 functions in both normal neurons and disease contexts requires careful consideration of therapeutic windows and potential off-target effects.

Research Directions

Model Systems

Current research employs multiple model systems to study H3F3A functions. iPSC-derived neurons provide patient-specific models for studying disease mechanisms and testing therapeutic interventions. Animal models including knock-in and conditional knockout systems allow investigation of H3.3 functions in living organisms. Organoid systems enable study of brain region-specific development and disease processes in three-dimensional cultures that better recapitulate brain architecture. Single-cell approaches are increasingly used to examine cell-type-specific dynamics and understand how H3.3 functions differ across neural cell populations.

Biomarkers

Several biomarker approaches are being developed for H3F3A-related conditions. H3K27M detection in cerebrospinal fluid provides a non-invasive diagnostic marker for DIPG that can be used to monitor disease progression and treatment response. Epigenetic signatures in blood may serve as accessible biomarkers for brain conditions involving chromatin changes. Imaging-based chromatin states represent an emerging approach to visualizing epigenetic alterations in living patients.

Cross-Links to NeuroWiki Pages

Related Mechanisms

• [Epigenetic Regulation in Neurodegeneration](/mechanisms/epigenetic-regulation)
• [Chromatin Dynamics and Neuroprotection](/mechanisms/chromatin-dynamics)
• [Gene Expression in Neurodegeneration](/mechanisms/gene-expression-dysregulation)

Related Cell Types

• [Neurons — General](/entities/neurons)
• [Neural Progenitor Cells](/cell-types/neural-progenitor-cells)

Related Diseases

• [Diffuse Intrinsic Pontine Glioma](/diseases/dipg)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](/diseases/huntingtons-disease)

Summary

H3F3A encodes histone H3.3, a replication-independent histone variant critical for chromatin regulation in the central nervous system. H3.3 plays essential roles in neuronal development, activity-dependent gene expression, synaptic plasticity, and epigenetic maintenance. The H3.3K27M mutation is a driver event in DIPG [@h3k27m-glioma], while altered H3.3 dynamics are implicated in AD, PD, and HD [@epigenetic-neurodegeneration]. Understanding H3.3's functions provides insights into disease mechanisms and therapeutic opportunities.

Key References

External Resources

• [NCBI Gene — H3F3A](https://www.ncbi.nlm.nih.gov/gene/3020)
• [UniProt — H3.3 (P84243)](https://www.uniprot.org/uniprot/P84243)
• [OMIM — H3F3A](https://www.omim.org/entry/601128)
• [COSMIC — H3F3A mutations](https://cancer.sanger.ac.uk/cosmic/gene/analysis)
• [UCSC Genome Browser — H3F3A](https://genome.ucsc.edu/)
• [Human Protein Atlas — H3F3A](https://www.proteinatlas.org/gene/H3F3A)

Pathway Diagram

The following diagram shows the key molecular relationships involving H3F3A — H3.3 Histone A discovered through SciDEX knowledge graph analysis: